Literature DB >> 4161055

Rubidomycin. A new agent active in the treatment of acute lymphoblastic leukaemia.

C Jacquillat, M Boiron, M Weil, J Tanzer, Y Najean, J Bernard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 4161055     DOI： 10.1016/s0140-6736(66)91751-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Cancer chemotherapy--the first twenty-five years.

Authors:  R B Scott
Journal:  Br Med J       Date:  1970-10-31

2.  Daunorubicin. Results in childhood leukaemia.

Authors:  R N Matthews; J H Colebatch
Journal:  Arch Dis Child       Date:  1972-04       Impact factor: 3.791

3.  Daunorubicin in acute leukaemia.

Authors:  R L Souhami; T A Prankerd
Journal:  Postgrad Med J       Date:  1970-05       Impact factor: 2.401

4.  Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia.

Authors:  C Paul; M Björkholm; I Christenson; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Treatment of acute nonlymphoblastic leukemia in adults with daunorubicin-DNA complex: a preliminary report.

Authors:  G Gahrton; M Björkholm; G Brenning; I Christenson; L Engstedt; S Franzén; B Gullbring; G Holm; C Högman; P Hörnsten; S Jameson; A Killander; C Simonsson-Lindemalm; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Paul; C Pauli; C Peterson; P Reizenstein; B Simonsson; K O Skårberg; A M Udén; B Wadman
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  A survey of the anthracycline derivatives in hematology.

Authors:  C Jacquillat; M Weil; M F Auclerc; J Maral; G Schaison; M Boiron; J Bernard
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 7.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.